Abstract:Proteasome inhibition is an innovative and promising approach for treating hematologic malignancies and may provide immunomodulatory effects. We have shown that systemic proteasome inhibition using bortezomib administered immediately following bone marrow transplantation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of graft-versus-tumor (GVT) effects in mice. Surprisingly, extended administration of bortezomib exacerbated GVHD-dependent mortality due to severe gut toxicity (Sun, et al. Blood, 106:3293–9, 2005). This suggested that a narrow therapeutic index for bortezomib administration may limit its application for prevention of tumor relapse in the patients who had previously undergone allogeneic BMT. In this study, we have extended the investigation to determine the relative importance of CD4+ and CD8+ T cells in the development of this GVHD-dependent gut toxicity as well as potentially increase GVT induced by extended bortezomib treatment. Using two MHC-mismatched BMT models, C57BL/6 or BALB/c recipients of a defined dose of CD4+ T cell-depleted allogeneic donor splenocytes had significantly reduced GVHD-dependent toxicity from prolonged bortezomib treatment (7.5–15 ug/dose given every 4–6 days beginning on the day of transplant for a total of 4–5 injections). No protection from toxicity was seen with donor CD8+ T cell depletion. Decreased bortezomib related gut toxicity was also seen with in vivo CD4+ T cell depletion after allogeneic BMT. Interestingly, depletion of the donor CD4+ T cells resulted in reduced serum TNF-αlevels correlating with the decreased bortezomib-induced toxicity. However, the recipients receiving prolonged bortezomib had high levels of serum IFN-γ produced by the remaining donor CD8+ T cells despite the absence of GVHD lethality. To confirm the role of CD4+ T cells in mediating the toxicity associated with prolonged bortezomib administration a multiple minor histocompatibility antigen mismatch model was used in which CD8+ T cells are the primary effector in GVHD. C3.SW donor splenocytes and BM were transferred into irradiated C57BL/6 recipients. Prolonged administration of bortezomib resulted in significantly lower GVHD-dependent toxicity in this strain combination confirming the importance of CD4+ T cells in mediating the GVHD-dependent toxicity. We then addressed the effects of continuous bortezomib administration on GVT responses. We used two different MHC-mismatch BMT models with recipients bearing either A20 lymphoma (H2d) or C1498 leukemia (H2b). Tumor-bearing mice receiving an allogeneic BMT with a defined dose of CD4+ T cell-depleted donor splenocytes below the normal threshold required for GVHD/GVT and prolonged bortezomib administration resulted in marked GVT responses. These observations suggest that bortezomib induced GVHD-dependent gut toxicity and increased GVT activity associated with prolonged administration can at least be partially separated by modulation of donor T cell subsets, particularly CD4+ T cells, in the donor graft. Thus prolonged administration of bortezomib together with CD8+ T cell mediated GVT results in synergistic augmentation of anti-tumor activity compared to either modality alone.

Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis

Bortezomib Therapeutic Effect is Associated with Expression of Fgfr3 in Multiple Myeloma Cells

An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,

Therapeutic Benefit of Bortezomib on Acute Graft-Versus-host Disease is Tissue Specific and is Associated with Interleukin-6 Levels.

Treatment of Chronic Graft-Versus-host Disease with Bortezomib.

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

Removal of Donor Cd4+T Cells Markedly Promotes Graft-Versus-Tumor (gvt) Effects and Inhibits Gvhd-Dependent Toxicity Associated with Prolonged Bortezomib Administration after Allogeneic Bmt.

Inhibition of Acute Graft-Versus-Host Disease with Retention of Graft-Versus-Tumor Effects by the Proteasome Inhibitor Bortezomib

Treatment with Bortezomib in a Patient with Heavily Pretreated Refractory T‐cell Lymphoblastic Lymphoma

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.

Differential Effects of Donor T-cell Cytokines on Outcome with Continuous Bortezomib Administration after Allogeneic Bone Marrow Transplantation

Differential Effects of Proteasome Inhibition by Bortezomib on Murine Acute Graft-Versus-host Disease (GVHD): Delayed Administration of Bortezomib Results in Increased GVHD-dependent Gastrointestinal Toxicity.

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma

Organ-Specific Protection from CD8+ T Cell-Mediated Acute Skin GVHD by Bortezomib Administration Correlates with Decreased IL-6.

Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression

Organ-Specific Protection by Bortezomib on the Treatment of Cutaneous Chronic and Acute GvHD

Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part Through the Inhibition of the Phosphatidylinositol 3-Kinase/akt Pathway

Use of bortezomib in B-cell non-Hodgkin's lymphoma.

Bortezomib Interferes with C-Kit Processing and Transforms the T(8;21)-Generated Fusion Proteins into Tumor-Suppressing Fragments in Leukemia Cells

Proteasome inhibitor bortezomib targeted tumor–endothelial cell interaction in T-cell leukemia/lymphoma